Artax Biopharma

Artax Biopharma is pioneering a new class of immunomodulators targeting the Nck protein to treat autoimmune diseases by rebalancing, rather than suppressing, the immune system. The company's lead asset, AX-158, is in Phase 2 development for psoriasis, with plans to expand into atopic dermatitis and rheumatoid arthritis. Founded in 2015 and led by an experienced management team, Artax aims to address a significant unmet need in autoimmunity with a potentially safer, more targeted therapeutic profile. Its technology platform offers a differentiated mechanism that could be applicable across multiple T-cell mediated conditions.

Platform of oral small molecule Nck modulators that inhibit the recruitment of the Nck protein to the T-cell receptor (TCR), modulating Signal 1 activation to rebalance the immune response without causing broad immunosuppression.

Artax competes in the crowded autoimmune disease space against dominant biologic drugs (anti-TNF, IL-17/23 inhibitors) and oral JAK inhibitors. Its key differentiation is the novel Nck mechanism aiming for immune rebalancing without broad suppression, a potential safety advantage. However, it must demonstrate compelling efficacy to displace established therapies.